Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primatesVictoria Koch, Sven Kronenberg, Martin Lechmann et al.|Journal of Immunotoxicology|2025Cited by 2
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBsOmar Abdelmotaleb, Christian Klein, Katharina Essig et al.|mAbs|2025Cited by 2
Abstract 1235: Impact of anti-CD3 and tumor-target binder affinities on <i>in-vitro</i> potency, <i>in-vivo</i> efficacy, and cytokine releaseOmar Abdelmotaleb, Christian Klein, Anneliese Schneider et al.|Cancer Research|2024Cited by 1
Abstract 2961: HLA-G-TCB (RG6353), a T cell bispecific antibody for the treatment of solid tumors in monotherapy and combination with immunomodulator agentsMeher Majety, Pablo Umaña, Carina Hage et al.|Cancer Research|2023Cited by 0